Entrectinib

Drug Profile

Entrectinib

Alternative Names: NMS-E628; RXDX-101; TrkA/TrkB/TrkC/ROS1/ALK inhibitor

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Ignyta; Nerviano Medical Sciences
  • Class Antineoplastics; Benzamides; Indazoles; Piperazines; Pyrans; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1-protein-inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Non-small cell lung cancer; Colorectal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Neuroblastoma
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 15 May 2017 Entrectinib receives Breakthrough Therapy status for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
  • 27 Apr 2017 Ignyta announces intention to file NDA with the US FDA for Solid tumours (TRK tissue agnostic) and Non-small cell lung cancer (ROS1 fusion positive) in 2018
  • 27 Apr 2017 Ignyta plans to market entrectinib for Solid tumours (TRK tissue agnostic) and Non-small cell lung cancer (ROS1 fusion positive) in USA in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top